<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.4//EN" "ep-patent-document-v1-4.dtd">
<ep-patent-document id="EP02776152B2" file="EP02776152NWB2.xml" lang="en" country="EP" doc-number="1451194" kind="B2" date-publ="20091216" status="n" dtd-version="ep-patent-document-v1-4">
<SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIE......FI....CY..TRBGCZEE....SK....................................</B001EP><B003EP>*</B003EP><B005EP>J</B005EP><B007EP>DIM360 Ver 2.15 (14 Jul 2008) -  2720000/0</B007EP></eptags></B000><B100><B110>1451194</B110><B120><B121>NEW EUROPEAN PATENT SPECIFICATION</B121><B121EP>After opposition procedure</B121EP></B120><B130>B2</B130><B140><date>20091216</date></B140><B190>EP</B190></B100><B200><B210>02776152.7</B210><B220><date>20021003</date></B220><B240><B241><date>20040430</date></B241><B242><date>20051024</date></B242><B243><date>20091216</date></B243></B240><B250>en</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>326958 P</B310><B320><date>20011003</date></B320><B330><ctry>US</ctry></B330><B310>334316 P</B310><B320><date>20011129</date></B320><B330><ctry>US</ctry></B330><B310>354939 P</B310><B320><date>20020211</date></B320><B330><ctry>US</ctry></B330></B300><B400><B405><date>20091216</date><bnum>200951</bnum></B405><B430><date>20040901</date><bnum>200436</bnum></B430><B450><date>20061004</date><bnum>200640</bnum></B450><B452EP><date>20060330</date></B452EP><B472><B475><date>20061004</date><ctry>AT</ctry><date>20070104</date><ctry>BG</ctry><date>20061004</date><ctry>CH</ctry><date>20061004</date><ctry>CY</ctry><date>20061004</date><ctry>CZ</ctry><date>20070104</date><ctry>DK</ctry><date>20061004</date><ctry>EE</ctry><date>20061004</date><ctry>FI</ctry><date>20070105</date><ctry>GR</ctry><date>20071003</date><ctry>IE</ctry><date>20061004</date><ctry>LI</ctry><date>20071003</date><ctry>LU</ctry><date>20071031</date><ctry>MC</ctry><date>20061004</date><ctry>SK</ctry><date>20061004</date><ctry>TR</ctry></B475></B472><B477><date>20091216</date><bnum>200951</bnum></B477></B400><B500><B510EP><classification-ipcr sequence="1"><text>C07D 498/06        20060101AFI20040428BHEP        </text></classification-ipcr><classification-ipcr sequence="2"><text>A61K  31/5383      20060101ALI20050425BHEP        </text></classification-ipcr><classification-ipcr sequence="3"><text>C07D 498/06        20060101ALN20050425BHEP        </text></classification-ipcr><classification-ipcr sequence="4"><text>C07D 265/00        20060101ALN20050425BHEP        </text></classification-ipcr><classification-ipcr sequence="5"><text>C07D 221/00        20060101ALN20050425BHEP        </text></classification-ipcr></B510EP><B540><B541>de</B541><B542>HERSTELLUNG VON LEVOFLOXACIN HEMIHYDRAT</B542><B541>en</B541><B542>PREPARATION OF LEVOFLOXACIN HEMIHYDRATE</B542><B541>fr</B541><B542>PREPARATION DE LEVOFLOXACINE HEMIHYDRATE</B542></B540><B560><B561><text>EP-A1- 0 444 678</text></B561><B561><text>WO-A-01/18005</text></B561><B561><text>WO-A1-00/50428</text></B561><B561><text>US-A- 5 521 310</text></B561><B561><text>US-A- 5 539 110</text></B561><B561><text>US-A- 5 545 737</text></B561><B562><text>KANG, SOON BANG ET AL: "An improved synthesis of levofloxacin" HETEROCYCLES , 45(1), 137-145 CODEN: HTCYAM; ISSN: 0385-5414, 1997, XP002325796</text></B562><B565EP><date>20050511</date></B565EP></B560></B500><B600><B620EP><parent><cdoc><dnum><anum>06020684.4</anum><pnum>1772457</pnum></dnum><date>20061002</date></cdoc><cdoc><dnum><anum>08015768.8</anum><pnum>1992629</pnum></dnum><date>20080908</date></cdoc></parent></B620EP></B600><B700><B720><B721><snm>NIDDAM-HILDESHEIM, Valerie</snm><adr><str>Pob 21,
Israelian</str><city>Ein Vered 40696</city><ctry>IL</ctry></adr></B721><B721><snm>GERSHON, Neomi</snm><adr><str>11 Nachshon Street</str><city>Kfar-Saba</city><ctry>IL</ctry></adr></B721><B721><snm>AMIR, Ehud</snm><adr><str>48/14 Tagor Str.</str><city>69341 Ramat-Aviv</city><ctry>IL</ctry></adr></B721><B721><snm>WIZEL, Shlomit</snm><adr><str>Yehuda Hanassi 2</str><city>49742 Petah Tiqva</city><ctry>IL</ctry></adr></B721></B720><B730><B731><snm>TEVA PHARMACEUTICAL INDUSTRIES LTD.</snm><iid>00211119</iid><irf>P019829EP NJN</irf><adr><str>5 Basel Street, 
P.O. Box 3190</str><city>49131 Petah Tiqva</city><ctry>IL</ctry></adr></B731></B730><B740><B741><snm>Nachshen, Neil Jacob</snm><sfx>et al</sfx><iid>00085471</iid><adr><str>D Young &amp; Co 
120 Holborn</str><city>London EC1N 2DY</city><ctry>GB</ctry></adr></B741></B740><B780><B781><dnum><text>01</text></dnum><date>20070704</date><kind>1</kind><snm>Ratiopharm GmbH</snm><iid>00093311</iid><adr><str>Graf-Arco-Strasse 3</str><city>89079 Ulm</city><ctry>DE</ctry></adr><B784><snm>Breuer, Markus</snm><iid>00083461</iid><adr><str>Breuer &amp; Müller Partnerschaft 
Patentanwälte 
Heimeranstrasse 35</str><city>80339 München</city><ctry>DE</ctry></adr></B784></B781></B780></B700><B800><B840><ctry>AT</ctry><ctry>BE</ctry><ctry>BG</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>CZ</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>EE</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>IE</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LU</ctry><ctry>MC</ctry><ctry>NL</ctry><ctry>PT</ctry><ctry>SE</ctry><ctry>SK</ctry><ctry>TR</ctry></B840><B860><B861><dnum><anum>US2002031850</anum></dnum><date>20021003</date></B861><B862>en</B862></B860><B870><B871><dnum><pnum>WO2003028664</pnum></dnum><date>20030410</date><bnum>200315</bnum></B871></B870></B800></SDOBI><!-- EPO <DP n="1"> -->
<description id="desc" lang="en">
<heading id="h0001"><b><u>FIELD OF THE INVENTION</u></b></heading>
<p id="p0001" num="0001">The present invention relates to a process for preparing levofloxacin hemihydrate.</p>
<heading id="h0002"><b><u>BACKGROUND OF THE INVENTION</u></b></heading>
<p id="p0002" num="0002">Levofloxacin is a broad spectrum synthetic antibiotic. Levofloxacin is the S-enantiomer of the racemate, ofloxacin, a fluoroquinolone antimicrobial agent. The antibacterial activity of ofloxacin resides primarily in the S-enantiomer. The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves the inhibition of DNA gyrase (bacterial topoisomerase II), an enzyme required for DNA replication, transcription repair and recombination. Levofloxacin is available as LEVAQUIN® which may be orally administered or administered intravenously.</p>
<p id="p0003" num="0003">Levofloxacin is a chiral fluorinated carboxyquinolone. Its chemical name is (S)-9-fluoro-2,3 -dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]1,4-benzoxazine- 6-carboxylic acid (CAS Registry No. 100986-85-4). The chemical structure of levofloxacin is shown as Formula I.
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="82" he="57" img-content="chem" img-format="tif"/></chemistry></p>
<p id="p0004" num="0004"><patcit id="pcit0001" dnum="US4382892A"><text>U.S. Patent No. 4,382,892</text></patcit> is directed toward pyrido[1,2,3-de][1,4]benzoxazine derivatives and methods of preparing them.</p>
<p id="p0005" num="0005"><patcit id="pcit0002" dnum="US5053407A"><text>U.S. Patent No. 5,053,407</text></patcit> is directed toward optically active pyridobenzoxazine derivatives, processes for preparing the same, and intermediates useful for preparing such derivatives.</p>
<p id="p0006" num="0006"><patcit id="pcit0003" dnum="US5051505A"><text>U.S. Patent No. 5,051,505</text></patcit> is directed toward processes for preparing piperazinyl quinolone derivatives. The process comprises reacting dihaloquinolones with piperazine derivatives and tetraalkyl ammonium halides in the presence of a polar solvent such as acetonitrile, dimethylformamide, pyridine, sulfolane and dimethyl sulfoxide.</p>
<p id="p0007" num="0007"><patcit id="pcit0004" dnum="US5155223A"><text>U.S. Patent No. 5,155,223</text></patcit> is directed toward the preparation of quinolinecarboxylic acids.</p>
<p id="p0008" num="0008"><patcit id="pcit0005" dnum="US5545737A"><text>U.S. Patent No. 5,545,737</text></patcit> discloses selectively producing a levofloxacin hemihydrate or monohydrate by controlling the water content of an aqueous solvent in which levofloxacin is dissolved during a crystallization.</p>
<heading id="h0003"><u>Levofloxacin Forms</u></heading>
<p id="p0009" num="0009">Three polymorphic forms (anhydrous α, β, γ) and two pseudopolymorphic forms (hemihydrate and monohydrate) of levofloxacin are mentioned in the literature. Hemihydrate and monohydrate forms are mentioned in <patcit id="pcit0006" dnum="EP0444678B1"><text>EP 0444 678 B1</text></patcit> and in <patcit id="pcit0007" dnum="US5545737A"><text>U.S. Patent No. 5,545,737</text></patcit>. These two patents are directed toward processes for the preparation of hemihydrate form free of monohydrate and for the preparation of monohydrate free of hemihydrate.</p>
<p id="p0010" num="0010">The article titled "<nplcit id="ncit0001" npl-type="s"><text>Effect of dehydration on the formation of Levofloxacine Pseudopolymorphs," Chem. Pharm. Bull. 43(4) 649-653 (1995)</text></nplcit>, examines the physical properties of the hydrates forms of levofloxacin. According to the article, heating the hemihydrate form resulted in a removal of the hydrated water to give anhydrous form γ. Further heating resulted in the formation of anhydrous form β, and then the formation of anhydrous form α. Heating of the monohydrate form resulted in a removal of the hydrated water to give anhydrous form α. Form γ and form α adsorbed water vapor rapidly under ordinary relative humidity conditions and transformed into the hemihydrate and monohydrate, respectively.</p>
<p id="p0011" num="0011">The present invention relates to the solid state physical properties of levofloxacin. Solid state physical properties include, for example, the flowability of the milled solid. Flowability affects the ease with which the material is handled<!-- EPO <DP n="2"> --> during processing into a pharmaceutical product. When particles of the powdered compound do not flow past each other easily, a formulation specialist must take that fact into account in developing a tablet or capsule formulation, which may necessitate the use of glidants such as colloidal silicon dioxide, talc, starch or tribasic calcium phosphate.</p>
<p id="p0012" num="0012">Another important solid state property of a pharmaceutical compound is its rate of dissolution in aqueous fluid. The rate of dissolution of an active ingredient in a patient's stomach fluid can have therapeutic consequences since it imposes an upper limit on the rate at which an orally-administered active ingredient can reach the patient's bloodstream. The rate of dissolution is also a consideration in formulating syrups, elixirs and other liquid medicaments. The solid state Form of a compound may also affect its behavior on compaction and its storage stability.</p>
<p id="p0013" num="0013">These practical physical characteristics are influenced by the conformation and orientation of molecules in the unit cell, which defines a particular polymorphic Form of a substance. The polymorphic Form may give rise to thermal behavior different from that of the amorphous material or another polymorphic Form. Thermal behavior is measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) and can be used to distinguish some polymorphic forms from others. A particular polymorphic Form may also give rise to distinct spectroscopic properties that may be detectable by powder X-ray crystallography, solid state C-NMR spectrometry and infrared spectrometry.</p>
<heading id="h0004"><b><u>SUMMARY OF THE INVENTION</u></b></heading>
<p id="p0014" num="0014">The present invention provides a method for preparing levofloxacin hemihydrate comprising: maintaining levofloxacin at a temperature of 70°C to 120°C in a first solvent selected from the group consisting of propylene-glycol-monomethylether, dimethyl acetamide and dimethylsulfoxide; adding a second polar solvent comprising water to precipitate the levofloxacin hemihydrate; and recovering levofloxacin hemihydrate.</p>
<p id="p0015" num="0015">The levofloxacin can be made by a process comprising reacting (S)-(-)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de][1,4]benzoxazine-6-carboxylic acid ("Compound I") with N-methyl piperazine to form levofloxacin, and recovering the levofloxacin. Compound I may react with N-methyl piperazine either in a polar solvent or as a neat mixture.</p>
<heading id="h0005"><b><u>DETAILED DESCRIPTION OF THE INVENTION</u></b></heading>
<p id="p0016" num="0016">As used herein, "crude" and "purified" are relative terms meaning less pure or more pure, respectively.</p>
<p id="p0017" num="0017">Unless indicated otherwise, the terms "levofloxacin" and "levofloxacin form" include the salts, hydrates, solvates and physiologically functional derivatives of levofloxacin. The term also includes all polymorphous forms of levofloxacin to the extent that they are not considered to be salts, hydrates, solvates or physiologically functional derivatives of levofloxacin.</p>
<p id="p0018" num="0018">The levofloxacin employed in the present invention may be prepared by a process comprising reacting (S)-(-)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4] benzoxazine-6-carboxylic acid ("Compound I") with N-methyl piperazine in a polar solvent, preferably at an elevated temperature, to form levofloxacin. The elevated temperature is preferably 70-120 °C. The levofloxacin can then be precipitated and recovered using techniques well known in the art. As used herein, the term "precipitated" includes the formation of a solid in a solution or an increase in the amount of solid in a slurry. The preparation of Compound I is described, for example, in <patcit id="pcit0008" dnum="US4382892A"><text>U.S. Patent No, 4,382,892</text></patcit>.</p>
<p id="p0019" num="0019">A suitable polar solvent is any that is capable of dissolving levofloxacin. Preferably, the polar solvent is dimethlysulfoxide (DMSO), an alcohol (preferably isobutanol), a ketone, propylene-glycol-monomethyl-ether (PGME) or dimethyl acetamide (DMA). As used herein, the term "polar solvent" is intended as a relative term to mean relatively more polar than another solvent.</p>
<p id="p0020" num="0020">The volume of solvent is from 14 ml to 4 ml per gram of Compound I. The solvent is preferably selected from the group consisting of isobutanol and PGME. The volume of solvent is preferably less than 3 ml per gram of the compound of Compound I. The solvent is preferably selected from the group consisting of DMSO and DMA. Advantageously, short reaction times are needed to obtain high yields with DMSO.</p>
<p id="p0021" num="0021">If DMSO is used as the solvent, the preferred volume of solvent is up to 3 ml solvent/g compound, more preferably 0.5 to 3 ml solvent/g compound, but more could be used. If PGME is used as the solvent, the preferred volume of solvent is 4 to 14 ml solvent/g compound, but more could be used.</p>
<p id="p0022" num="0022">Optionally, the process may further comprise adding an anti-solvent to the solvent after the reacting step to increase yield. As used herein, the term "anti-solvent" means a liquid in which levofloxacin is poorly soluble such that the addition of an anti-solvent to a solvent reduces the solubility of a levofloxacin. Preferably, the anti-solvent is one or more of the following: n-heptane, hexane, isopropyl alcohol, isopropyl alcohol in water (about 5% isopropyl alcohol or greater), butanol, acetonitrile, methyl ethyl ketone, or DMSO/water. When the solvent is propylene glycol monomethyl ether or isobutanol, the preferred antisolvent is heptane or hexane. When the solvent is DMSO, the preferred antisolvent is isopropanol.<!-- EPO <DP n="3"> --></p>
<p id="p0023" num="0023">Alternatively, Compound I may be reacted with N-methyl piperazine as a neat mixture. In this case, Compound I is preferably dissolved in a suspension of the N-methyl piperazine.</p>
<p id="p0024" num="0024">The N-methyl piperazine may be in molar excess over Compound L Preferably, the molar excess is from 2 to 4 times. More preferably, the molar excess is from 2 to 2.5 times.</p>
<p id="p0025" num="0025">The preferred duration of the reacting step will depend on balancing the desire for the reaction to go to completion, which in turn depends on the reaction conditions, particularly the choice of solvent and the temperature, while maximizing efficiency and/or minimizing side reactions and/or degradation. For example, the reacting step is typically performed for a time period from 1 h to 24 h when a solvent is used. When the reaction is performed as a neat mixture, the time period for the reaction may be less than 1 h.</p>
<p id="p0026" num="0026">The reacting step may be performed at a temperature as high as 110°C to 120°C or higher. When the reaction is performed as a neat mixture, the reacting step is preferably performed at about the reflux temperature.</p>
<heading id="h0006"><b><u>Preparation of Levofloxacin hemihydrate</u></b></heading>
<p id="p0027" num="0027">In accordance with the present invention, the method for preparing levofloxacin hemihydrate comprises maintaining levofloxacin at a temperature of 70°C to 120°C, in a first solvent selected from the group consisting of propylene-glycol-monomethylether, dimethylacetamide and dimethylsulfoxide; adding a second polar solvent comprising water, and recovering levofloxacin hemihydrate. Preferably, this method further comprises cooling and maintaining the levofloxacin-solvent mixture at a below-ambient temperature.</p>
<p id="p0028" num="0028">The levofloxacin may be heated to a first elevated temperature. However, it is preferable that the levofloxacin is first synthesized, such as by reacting Compound I with N-methyl piperazine, described above, and the reaction mixture is then brought directly to a temperature of 60°C to 80°C for adding the second polar solvent. The temperature at which levofloxacin in maintained depends on the particular solvent, is generally in the range of 70 °C to 120 °C, preferably 80 °C to 85 °C. The temperature of the mixture at which the second polar solvent is added depends on the particular polar solvent, and is generally in the range of 60 °C to 80 °C, preferably 75 °C to 79 °C.</p>
<p id="p0029" num="0029">It is preferred that the second polar solvent is added to the levofloxacin, preferably slowly, at a temperature of 60°C to 80°C The second polar solvent is preferably added over about 2 h. Optionally, the mixture is maintained, preferably with stirring or other agitation, for an additional period of time.</p>
<p id="p0030" num="0030">Recovering the levofloxacin typically includes cooling the mixture to precipitate the levofloxacin followed by filtration.</p>
<p id="p0031" num="0031">For the preparation of levofloxacin hemihydrate, the second polar solvent comprises water, preferably a mixture of isopropanol and water, more preferably about 3% to about 4% (v/v) water. In this embodiment, the first elevated temperature is preferably about 80°C and the second elevated temperature is preferably about 75 °C. Preferably, the second polar solvent is added dropwise over about 2 hours. Following the adding step, the levofloxacin-polar-solvent mixture is slowly cooled to a below-ambient temperature, preferably in the range of 0 °C to 20 °C, more preferably about 5°C. Preferably, the cooling step occurs over 1 to 10 hours, more preferably about 4 hours. Preferably, the below-ambient temperature is maintained for an additional about 2 hours.</p>
<p id="p0032" num="0032">The function and advantages of these and other embodiments of the present invention will be more fully understood from the examples below. The following examples are intended to illustrate the benefits of the present invention, but do not exemplify the full scope of the invention.</p>
<heading id="h0007"><b><u>EXAMPLES</u></b></heading>
<heading id="h0008"><b><u>Example 1: Synthesis of Levofloxacin in DMSO</u></b></heading>
<p id="p0033" num="0033">5g (17.8 mmole) of (S)-(-)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro -7H-pyrido [1,2,3-de][1,4]benzoxazine-6-carboxylic acid was put in suspension in 2.5 mL of DMSO and 4.2 mL (37.9 mmole) of N-methyl piperazine. The reaction mixture was heated to 120 °C and the suspension became soluble. After 2.5 h the reaction was completed. The mixture was then cooled to 70 °C and isopropanol (25 mL) was then added at this temperature. The reaction mixture was slurried for 1 h at ambient temperature, filtered, and dried overnight to obtain 5.86 g (91.3 %) of levofloxacin.</p>
<heading id="h0009"><b><u>Example 2: Synthesis of Levofloxacin in PGME</u></b></heading>
<p id="p0034" num="0034">3g (10.67 mmole) of (S)-(-)-9,10-difluoro-3-methyl -7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de][1,4]benzoxazine-6-carboxylic acid was put in suspension in 30 mL of PGME and 4.75 mL (43 mmole) of N-methyl piperazine. The reaction mixture was heated to reflux for 23 hours until completion of the reaction. During that time, the reaction mixture became soluble. The mixture was then cooled to 90°C and n-Heptane (10 mL) was added at this temperature. The reaction<!-- EPO <DP n="4"> --> mixture was then cooled to 0°C and the precipitation occurred around 65°C. The reaction was left at 0°C for 3 hours, filtrated under vacuum and dried overnight to obtain 2.98 g (77.3%) of levofloxacin.</p>
<heading id="h0010"><b><u>Example 3: Synthesis of Levofloxacin in Isobutanol</u></b></heading>
<p id="p0035" num="0035">3g (10.67 mmole) of (S)-(-)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H- pyrido [1,2,3-de][1,4]benzoxazine-6-carboxylic acid was put in suspension in 21 mL of isobutanol and 4.75 mL (43 mmole) of N-methyl piperazine. The reaction mixture was heated to reflux for 6 hours, then slurried at ambient temperature for 60 hours and heated again to reflux for 7 hours until completion of the reaction. During that time, the reaction mixture became soluble at reflux temperature. The mixture was them cooled to 0 °C, filtered under vacuum, washed with 7 mL isobutanol and 10 mL n-heptane, and dried overnight to obtain 2.83 g (77.3%) of levofloxacin.</p>
<heading id="h0011"><b><u>Example 4: Synthesis of Levofloxacin (Neat)</u></b></heading>
<p id="p0036" num="0036">5g (17.79 mmole) of (S)-(-) -9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de][1,4]benzoxazine-6-carboxylic acid was put in suspension in 6.8 mL (0.06 mole) of N-methyl piperazine. The reaction mixture was heated to reflux for 40 minutes until completion of the reaction. The mixture was then cooled to 80 °C. IPA (10 mL) and n-heptane (10 mL) were added at this temperature. The solid was filtrated under vacuum and rinsed with n-heptane. The mother liquor also gave a precipitate after addition of n-heptane. Both precipitates were filtrated under vacuum and dried overnight to yield 4.9 g (76%) levofloxacin.</p>
<heading id="h0012"><b><u>Example 5: Synthesis of Levofloxacin in DMA</u></b></heading>
<p id="p0037" num="0037">10 g (35.6mmole) of (S)-(-)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de][1,4]benzoxazine-6-carboxylic acid was put in suspension in 5 mL of DMA (dimethyl acetamide) and 8.3 mL (75 mmole) of N-methyl piperazine. The reaction mixture was heated to 110°C until the complete conversion of the starting material, about 1.5 h. The reaction mixture was then cooled to 80°C and 60 ml of isopropyl alcohol was added. The reaction mixture was then slurried for 3 hours at ambient temperature filtered under vacuum, washed with 40 ml IPA and dried in vacuum oven overnight to obtain 11.48 g (89.3%) of levofloxacin.</p>
<heading id="h0013"><b><u>Example 6: Synthesis of Hemihydrate</u></b></heading>
<p id="p0038" num="0038">In 1 liter reactor equipped with a mechanical stirrer, a condenser and a thermometer, heated at 80 °C, was charged 87.5 g (0.31 mole) of (S)-(-)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid, 61.3 mL DMSO and 86.3 mL (0.77 mole) of N-methylpiperazine. The slurry was stirred at a rate of 250 rpm under nitrogen atmosphere at 80 °C until completion of the reaction (monitoring by HPLC). Then the slurry was cooled to 75 °C and a mixture of isopropanol (675 mL) and water (25 mL) was added dropwise at this temperature during 2 hours. The slurry was then cooled to 5°C during 4 hours, maintained at this temperature for 2 hours and filtrated under vacuum at this temperature. The solid was then washed with 175 mL of isopropanol (2 rinses) and dried under vacuum to obtain levofloxacin hemihydrate.</p>
<heading id="h0014"><b><u>Example 7: Preparation of Hemihydrate using DMSO/Water</u></b></heading>
<p id="p0039" num="0039">1g of levofloxacin crude was put in suspension in 1.5 ml of DMSO. The mixture was heated to 108°C until complete dissolution of the material. Then H<sub>2</sub>O (7.5 ml) was added over 10 minutes and the mixture was cooled to RT. The precipitate was filtrated under vacuum, washed with 1 ml of a mixture DMSO:H<sub>2</sub>O 1:5 and dried at 60°C in an airflow oven to give 840 mg (84%) of purified levofloxacin hemihydrate.</p>
</description><!-- EPO <DP n="5"> -->
<claims id="claims01" lang="en">
<claim id="c-en-01-0001" num="0001">
<claim-text>A method for preparing levofloxacin hemihydrate comprising:
<claim-text>maintaining levofloxacin at a temperature of 70°C to 120°C in a first solvent selected from the group consisting of propylene-glycol-monomethylether (PGME), dimethylacetamide (DMA) and dimethylsulfoxide (DMSO),</claim-text>
<claim-text>adding a second polar solvent comprising water to precipitate the levofloxacin hemihydrate; and</claim-text>
<claim-text>recovering levofloxacin hemihydrate.</claim-text></claim-text></claim>
<claim id="c-en-01-0002" num="0002">
<claim-text>A method according to Claim 1 wherein the levofloxacin is maintained at a temperature of 80°C to 85°C in the first solvent.</claim-text></claim>
<claim id="c-en-01-0003" num="0003">
<claim-text>A method according to any preceding claim wherein the second polar solvent is added at a temperature of 60°C to 80°C.</claim-text></claim>
<claim id="c-en-01-0004" num="0004">
<claim-text>A method according to Claim 3 wherein the second polar solvent is added at a temperature of 75°C to 79°C.</claim-text></claim>
<claim id="c-en-01-0005" num="0005">
<claim-text>A method according to any preceding claim wherein the second polar solvent is added over about 2 hours.</claim-text></claim>
<claim id="c-en-01-0006" num="0006">
<claim-text>A method according to Claim 1 wherein the second polar solvent comprises a mixture of isopropanol and water.</claim-text></claim>
<claim id="c-en-01-0007" num="0007">
<claim-text>A method according to Claim 6 wherein the mixture of isopropanol and water contains 3% to 4% (v/v) water.</claim-text></claim>
<claim id="c-en-01-0008" num="0008">
<claim-text>A method according to Claim 6 or Claim 7 wherein the levofloxacin is maintained at a temperature of about 80°C in the first solvent and the second polar solvent is added at a temperature of about 75°C.</claim-text></claim>
<claim id="c-en-01-0009" num="0009">
<claim-text>A method according to any preceding claim wherein the levofloxacin is prepared by a process comprising:
<claim-text>reacting (S)-(-)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid with N-methyl piperazine at a temperature of 78°C to 120°C to form levofloxacin; and precipitating the levofloxacin.</claim-text></claim-text></claim>
</claims><!-- EPO <DP n="6"> -->
<claims id="claims02" lang="de">
<claim id="c-de-01-0001" num="0001">
<claim-text>Verfahren zur Herstellung von Levofloxacin-Hemihydrat, welches folgendes umfaßt:
<claim-text>Halten von Levofloxacin bei einer Temperatur von 70°C bis 120°C in einem ersten Lösungsmittel, ausgewählt aus der Gruppe bestehend aus Propylenglycol-Monomethylether (PGME), Dimethylacetamid (DMA) und Dimethylsulfoxid (DMSO),</claim-text>
<claim-text>Zugeben eines zweiten polaren Lösungsmittels, welches Wasser enthält, um das Levofloxacin-Hemihydrat zu präzipitieren, und</claim-text>
<claim-text>Gewinnen von Levoffoxacin-Hemihydrat.</claim-text></claim-text></claim>
<claim id="c-de-01-0002" num="0002">
<claim-text>Verfahren nach Anspruch 1, wobei das Levofloxacin bei einer Temperatur von 80°C bis 85°C in dem ersten Lösungsmittel gehalten wird.</claim-text></claim>
<claim id="c-de-01-0003" num="0003">
<claim-text>Verfahren nach einem der vorangegangenen Ansprüche, wobei das zweite polare Lösungsmittel bei einer Temperatur von 60°C bis 80°C zugegeben wird.</claim-text></claim>
<claim id="c-de-01-0004" num="0004">
<claim-text>Verfahren nach Anspruch 3, wobei das zweite polare Lösungsmittel bei einer Temperatur von 75°C bis 79°C zugegeben wird.</claim-text></claim>
<claim id="c-de-01-0005" num="0005">
<claim-text>Verfahren nach einem der vorangegangenen Ansprüche, wobei das zweite polare Lösungsmittel über etwa 2 Stunden zugegeben wird.</claim-text></claim>
<claim id="c-de-01-0006" num="0006">
<claim-text>Verfahren nach Anspruch 1, wobei das zweite polare Lösungsmittel ein Gemisch aus Isopropanol und Wasser umfaßt.</claim-text></claim>
<claim id="c-de-01-0007" num="0007">
<claim-text>Verfahren nach Anspruch 6, wobei das Gemisch aus Isopropanol und Wasser 3% bis 4% (v/v) Wasser enthält.</claim-text></claim>
<claim id="c-de-01-0008" num="0008">
<claim-text>Verfahren nach Anspruch 6 oder Anspruch 7, wobei das Levofloxacin bei einer Temperatur von etwa 80°C in dem ersten Lösungsmittel gehalten wird und das zweite polare Lösungsmittel bei einer Temperatur von etwa 75°C zugegeben wird.</claim-text></claim>
<claim id="c-de-01-0009" num="0009">
<claim-text>Verfahren nach einem der vorangegangenen Ansprüche, wobei das Levofloxacin nach einem Verfahren hergestellt wird, welches folgendes umfaßt:<!-- EPO <DP n="7"> -->
<claim-text>Umsetzen von (S)-(-)-9,10-Difluor-3-methyl-7-oxo-2,3-dihydro-7H-pyrido-[1,2,3-de][1,4]-benzoxazin-6-carbonsäure mit N-Methylpiperazin bei einer Temperatur von 70°C bis 120°C unter Bildung von Levofloxacin und</claim-text>
<claim-text>Präzipitieren von Levofloxacin,</claim-text></claim-text></claim>
</claims><!-- EPO <DP n="8"> -->
<claims id="claims03" lang="fr">
<claim id="c-fr-01-0001" num="0001">
<claim-text>Procédé de préparation de lévofloxacine hémihydrate comprenant les étapes consistant à :
<claim-text>- maintenir la lévofloxacine à une température de 70 °C à 120 °C dans un premier solvant choisi dans le groupe composé par le propylène-glycol-monométhyl-éther (PGME), le diméthylacétamide (DMA) et le diméthyl sulfoxyde (DMSO).</claim-text>
<claim-text>- ajouter un second solvant polaire comprenant de l'eau pour précipiter le lévofloxacine hémihydrate ; et</claim-text>
<claim-text>- récupérer le lévofloxacine hémihydrate.</claim-text></claim-text></claim>
<claim id="c-fr-01-0002" num="0002">
<claim-text>Procédé selon la revendication 1, dans lequel la lévofloxacine est maintenue à une température de 80°C à 85 °C dans le premier solvant.</claim-text></claim>
<claim id="c-fr-01-0003" num="0003">
<claim-text>Procédé selon l'une quelconque des revendications précédentes, dans lequel le second solvant polaire est ajouté à une température de 60°C à 80 °C.</claim-text></claim>
<claim id="c-fr-01-0004" num="0004">
<claim-text>Procédé selon la revendication 3, dans lequel le second solvant polaire est ajouté à une température de 75 °C à 79 °C.</claim-text></claim>
<claim id="c-fr-01-0005" num="0005">
<claim-text>Procédé selon l'une quelconque des revendications précédentes, dans lequel le second solvant polaire est ajouté sur une période d'environ 2 heures.</claim-text></claim>
<claim id="c-fr-01-0006" num="0006">
<claim-text>Procédé selon la revendication 1, dans lequel le second solvant polaire comprend un mélange d'isopropanol et d'eau.</claim-text></claim>
<claim id="c-fr-01-0007" num="0007">
<claim-text>Procédé selon la revendication 6, dans lequel le mélange d'isopropanol et d'eau contient de 3 % à 4 % (v/v) d'eau.</claim-text></claim>
<claim id="c-fr-01-0008" num="0008">
<claim-text>Procédé selon la revendication 6 ou la revendication 7, dans lequel la lévofloxacine est maintenue à une température d'environ 80°C dans le premier solvant et le second solvant polaire est ajouté à une température d'environ 75 °C.<!-- EPO <DP n="9"> --></claim-text></claim>
<claim id="c-fr-01-0009" num="0009">
<claim-text>Procédé selon l'une quelconque des revendications précédentes, dans lequel la lévofloxacine est préparée par un procédé comprenant les étapes consistant à:
<claim-text>- faire réagir de l'acide (S)-(-)-9,10-difluoro-3-méthyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylique avec de la N-méthyl pipérazine à une température de 70 °C à 120°C pour former de la lévofloxacine ;<br/>
et</claim-text>
<claim-text>- précipiter la lévofloxacine.</claim-text></claim-text></claim>
</claims>
<ep-reference-list id="ref-list">
<heading id="ref-h0001"><b>REFERENCES CITED IN THE DESCRIPTION</b></heading>
<p id="ref-p0001" num=""><i>This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.</i></p>
<heading id="ref-h0002"><b>Patent documents cited in the description</b></heading>
<p id="ref-p0002" num="">
<ul id="ref-ul0001" list-style="bullet">
<li><patcit id="ref-pcit0001" dnum="US4382892A"><document-id><country>US</country><doc-number>4382892</doc-number><kind>A</kind></document-id></patcit><crossref idref="pcit0001">[0004]</crossref><crossref idref="pcit0008">[0018]</crossref></li>
<li><patcit id="ref-pcit0002" dnum="US5053407A"><document-id><country>US</country><doc-number>5053407</doc-number><kind>A</kind></document-id></patcit><crossref idref="pcit0002">[0005]</crossref></li>
<li><patcit id="ref-pcit0003" dnum="US5051505A"><document-id><country>US</country><doc-number>5051505</doc-number><kind>A</kind></document-id></patcit><crossref idref="pcit0003">[0006]</crossref></li>
<li><patcit id="ref-pcit0004" dnum="US5155223A"><document-id><country>US</country><doc-number>5155223</doc-number><kind>A</kind></document-id></patcit><crossref idref="pcit0004">[0007]</crossref></li>
<li><patcit id="ref-pcit0005" dnum="US5545737A"><document-id><country>US</country><doc-number>5545737</doc-number><kind>A</kind></document-id></patcit><crossref idref="pcit0005">[0008]</crossref><crossref idref="pcit0007">[0009]</crossref></li>
<li><patcit id="ref-pcit0006" dnum="EP0444678B1"><document-id><country>EP</country><doc-number>0444678</doc-number><kind>B1</kind></document-id></patcit><crossref idref="pcit0006">[0009]</crossref></li>
</ul></p>
<heading id="ref-h0003"><b>Non-patent literature cited in the description</b></heading>
<p id="ref-p0003" num="">
<ul id="ref-ul0002" list-style="bullet">
<li><nplcit id="ref-ncit0001" npl-type="s"><article><atl>Effect of dehydration on the formation of Levofloxacine Pseudopolymorphs</atl><serial><sertitle>Chem. Pharm. Bull.</sertitle><pubdate><sdate>19950000</sdate><edate/></pubdate><vid>43</vid><ino>4</ino></serial><location><pp><ppf>649</ppf><ppl>653</ppl></pp></location></article></nplcit><crossref idref="ncit0001">[0010]</crossref></li>
</ul></p>
</ep-reference-list>
</ep-patent-document>
